Mitochondrial Disruption and GATD3 Alterations Drive Right Ventricular Failure in HFpEF

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Circulation: Heart Failure https://doi.org/10.1161/CIRCHEARTFAILURE.126.014620 
Dr. Farhan Raza  et al.

Points

Heart failure with preserved ejection fraction affects roughly three million Americans and carries a 15 percent annual mortality rate when complicated by pulmonary hypertension.
Researchers evaluated forty-eight patients using invasive cardiac catheterization, cardiac magnetic resonance imaging, and tissue biopsies to analyze right heart performance.
Right ventricular dysfunction was identified as the primary predictor of hospitalization and mortality compared to conventional left ventricular filling metrics.
Genetic sequencing revealed disrupted mitochondrial bioenergetics and altered expression of metabolic regulatory genes including GATD3 in failing right ventricular tissue.
Large-scale validation across nearly fifty thousand UK Biobank participants highlighted metabolic hormone pathways as promising targets for precise therapeutic development.

Summary

This study evaluated the pathophysiology and prognostic determinants of heart failure with preserved ejection fraction (HFpEF) accompanied by pulmonary hypertension (PH-HFpEF), a clinical phenotype affecting approximately 3,000,000 adults in the United States. Given that more than 80% of HFpEF patients develop secondary pulmonary hypertension—a combined entity associated with a 15% annual mortality rate—the research sought to identify physiological predictors of adverse outcomes and elucidate cellular mechanisms driving disease progression. Led by Farhan Raza at the University of Wisconsin–Madison, the investigation integrated invasive right heart catheterization, 4D flow cardiac MRI, and endomyocardial biopsies to characterize cardiovascular mechanics.

Phenotypic analysis of 48 PH-HFpEF patients demonstrated that right ventricular (RV) performance, rather than conventional left heart metrics, serves as the primary determinant of clinical outcomes. Patients exhibiting right ventricular dysfunction experienced significantly higher rates of all-cause mortality and heart failure hospitalizations. Biopsy analysis via long-read RNA sequencing revealed distinct transcriptomic alterations in RV-dysfunctional cohorts, marked by profound disruption of mitochondrial energy production, abnormal cellular transport, and differential expression of metabolic regulatory genes, notably GATD3.

Multimodal replication across a cohort of 49,396 participants from the UK Biobank further identified C1QTNF1, a protective metabolic hormone, as a potentially causal molecular factor in heart failure development. These findings indicate that downstream right ventricular failure in PH-HFpEF is driven by impaired cellular bioenergetics and metabolic decompensation. The authors conclude that therapeutic strategies must pivot from empirical vasodilation toward phenotype-directed, mechanism-based interventions targeting mitochondrial bioenergetics and right ventricular preservation.

Link to the article: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.126.014620

References

Raza, F., Gregorich, Z. R., Freeman, J., Moore, B., Houston, T., Garcia-Arango, M., Lechuga, C. G., Chen, Y., Sahai, A., El Shaer, A., Korcarz, C., Cui, K., Park, Y., Jones, K., Tu, W., Runo, J., Schulte, J. J., Nagpal, P., Ge, Y., … Guo, W. (2026). Multimodal framework of left heart-pulmonary vascular remodeling underlying right ventricular failure in ph-hfpef. Circulation: Heart Failure, e014620. https://doi.org/10.1161/CIRCHEARTFAILURE.126.014620